Understand the source comparison
ARA-290 Results Timeline: Tissue Type Comparison
The ARA-290 results timeline varies by tissue type and injury model. Understanding these differences prevents misinterpretation of research outcomes. Peripheral nerve (small fiber neuropathy) Pain reduction, cytokine normalization Intraepidermal nerve fiber de
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The ARA-290 results timeline varies by tissue type and injury model. Understanding these differences prevents misinterpretation of research outcomes.
- Peripheral nerve (small fiber neuropathy)
- Pain reduction, cytokine normalization
- Intraepidermal nerve fiber density increase, corneal nerve fiber length improvement
- Axonal sprouting, Schwann cell activation, reduced neuroinflammation
- Requires 12-week observation minimum. Structural nerve changes lag symptom improvement significantly
- Renal tubular epithelium (CKD, AKI models)
- Reduced apoptosis, stabilized GFR
- Tubular regeneration, reduced fibrosis, improved creatinine clearance
- Tubular cell survival signaling, anti-fibrotic macrophage polarization
- Functional markers (GFR, creatinine) improve earlier than histological repair. Both timelines required
- Cardiac tissue (ischemia-reperfusion injury)
- Reduced infarct expansion, cytokine modulation
- Improved ejection fraction, reduced scar size, capillary density increase
- Cardiomyocyte survival, angiogenesis, reduced apoptotic signaling
- Acute cardioprotection at 48–72 hours distinct from long-term remodeling at 8–12 weeks
- Endothelial cells (vascular injury, diabetic vasculopathy)
- Reduced endothelial permeability, improved nitric oxide bioavailability
- Capillary density restoration, reduced microvascular rarefaction
- eNOS upregulation, reduced oxidative stress, VEGF-independent angiogenesis
- Functional microvascular improvements measurable via imaging at week 6–8
- Immune cells (macrophages, T-cells)
- M1 to M2 macrophage shift, reduced pro-inflammatory cytokine secretion
- Sustained anti-inflammatory phenotype, tissue-resident macrophage reprogramming
- NF-κB inhibition, STAT3 activation in macrophages
- Immune modulation is prerequisite for tissue repair. Occurs fastest but sustains throughout timeline
- The bottom line: no tissue type shows maximal ARA-290 benefit before week 6. Most require 8–12 weeks for structural outcomes to reach statistical significance. Research protocols that truncate observation windows below 8 weeks systematically underestimate the compound's therapeutic potential.